Pluristem Therapeutics Inc.
PSTI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $316 | $490 | $427 | $185 |
| % Growth | -35.5% | 14.8% | 130.8% | – |
| Cost of Goods Sold | $201 | $317 | $291 | $74 |
| Gross Profit | $115 | $173 | $136 | $111 |
| % Margin | 36.4% | 35.3% | 31.9% | 60% |
| R&D Expenses | $3,961 | $1,443 | $3,235 | $3,170 |
| G&A Expenses | $2,534 | $790 | $2,493 | $2,143 |
| SG&A Expenses | $2,534 | $790 | $2,493 | $2,143 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,495 | $2,233 | $5,728 | $5,313 |
| Operating Income | -$6,380 | -$2,791 | -$5,592 | -$5,202 |
| % Margin | -2,019% | -569.6% | -1,309.6% | -2,811.9% |
| Other Income/Exp. Net | $248 | -$6,053 | -$743 | $0 |
| Pre-Tax Income | -$6,132 | -$8,844 | -$6,335 | $1,847 |
| Tax Expense | $0 | -$121 | $0 | $0 |
| Net Income | -$6,132 | $8,987 | -$6,335 | $1,847 |
| % Margin | -1,940.5% | 1,834.1% | -1,483.6% | 998.4% |
| EPS | -0.65 | -1.78 | -0.94 | -0.53 |
| % Growth | 63.5% | -89.4% | -77.4% | – |
| EPS Diluted | -0.65 | -1.78 | -0.94 | -0.53 |
| Weighted Avg Shares Out | 89,956 | 63,370 | 65,636 | 5,553 |
| Weighted Avg Shares Out Dil | 89,956 | 63,370 | 65,636 | 5,553 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$678 | $0 | $0 |
| Interest Expense | $229 | -$1,417 | $212 | $211 |
| Depreciation & Amortization | $130 | -$251 | $0 | $0 |
| EBITDA | -$5,773 | -$10,512 | -$5,592 | -$5,202 |
| % Margin | -1,826.9% | -2,145.3% | -1,309.6% | -2,811.9% |